NDR1 inhibits the progression of colorectal cancer, T-cell lymphoma, glioblastoma and prostate cancer (Cornils et al., 2010; Zhang et al., 2015; Yue et al., 2018; Chen et al., 2021; Khan et al., 2023), also plays an important role in infection, inflammation and immunity (Shi et al., 2012; Wen et al., 2015; Ma et al., 2017; Ye et al., 2020) and promotes apoptosis and autophagy (Vichalkovski et al., 2008a; Joffre et al., 2015). Here, STK38 is linked to prostate cancer.